Related Experiment Video
Updated: Aug 17, 2026
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Acquisition of resistance to 6-azauridine through DNA amplification in neoplastic but not normal osteoblasts
D L Daniel1, J Tonzetich, M I Chernin
1Biology Department, Bucknell University, Lewisburg, PA 17837.
Abstract:
In this communication, we have characterized the resistance to AZUrd in tumorigenic mouse C3H-OS osteosarcoma cells and non-tumorigenic MC3T3-E1 osteoblast cells. DNA and RNA blot analysis showed a 30-fold increase in UMP synthase specific DNA and a 10-fold increase in mRNA, respectively, in resistant versus non-resistant C3H-OS cells. No corresponding increases in either UMP synthetase DNA or mRNA were evident in resistant MC3T3-E1 osteoblasts. Karyotype analysis of MC3T3-E1 and C3H-OS cells revealed translocations in the resistant cells. Regardless of drug-sensitive or resistant phenotype, the normal and neoplastic cells exhibited aneuploidy which was significantly more pronounced in the non-resistant tumor cells. Additionally, the number of chromosomes decreased in all resistant cells whether normal or neoplastic. We conclude that genomic instability in neoplastic cells is a prerequisite for the generation of drug resistant variants via the process of gene amplification.
Insights
Tumorigenic cells develop AZUrd resistance through gene amplification, evidenced by increased UMP synthase DNA and mRNA. Genomic instability in cancer cells is key to generating drug-resistant variants.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- AZUrd is a chemotherapeutic agent used in cancer treatment.
- Drug resistance is a major challenge in cancer therapy.
- Understanding the mechanisms of drug resistance is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the mechanisms of AZUrd resistance in osteosarcoma cells.
- To compare AZUrd resistance between tumorigenic and non-tumorigenic cells.
- To explore the role of genomic instability in drug resistance.
Main Methods:
- Cell culture of C3H-OS (tumorigenic) and MC3T3-E1 (non-tumorigenic) cells.
- DNA and RNA blot analysis to quantify UMP synthase gene and mRNA levels.
- Karyotype analysis to assess chromosomal abnormalities.
Main Results:
- Resistant C3H-OS cells showed a 30-fold increase in UMP synthase DNA and a 10-fold increase in mRNA compared to non-resistant cells.
- No significant changes in UMP synthase DNA or mRNA were observed in resistant MC3T3-E1 cells.
- Karyotype analysis revealed translocations in resistant cells of both types.
- Aneuploidy was more pronounced in non-resistant tumor cells, while resistant cells (both normal and neoplastic) exhibited a decrease in chromosome number.
Conclusions:
- Gene amplification of UMP synthase is a key mechanism for AZUrd resistance in tumorigenic osteosarcoma cells.
- Genomic instability in neoplastic cells is a prerequisite for developing drug-resistant variants through gene amplification.
- The study highlights the complex interplay between genomic alterations and drug resistance in cancer.
